Last reviewed · How we verify
Sevoflurane and isoflurane
At a glance
| Generic name | Sevoflurane and isoflurane |
|---|---|
| Also known as | Sevorane/isoflurane |
| Sponsor | UMC Utrecht |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival (PHASE3)
- Sevoflurane/Dexmedetomidine vs. Isoflurane for Pediatric Emergence Delirium (PHASE3)
- Total Intravenous Anesthesia (TIVA) Versus Inhalational Anesthesia at The End of Laparoscopic Obstetric Surgery Regarding Postoperative Nausea and Vomiting (NA)
- GA + ESP vs. SA + ESP in Lumbar Decompression Surgeries (PHASE3)
- Impact of Isoflurane and Sevoflurane on Oxidative Stress in Patients Undergoing Laparoscopic Cholecystectomy (NA)
- Delirium Reduction by Volatile Anesthesia in Cardiac Surgery (PHASE4)
- The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections (NA)
- Interaction of Volatile Anesthetics With Magnesium (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sevoflurane and isoflurane CI brief — competitive landscape report
- Sevoflurane and isoflurane updates RSS · CI watch RSS
- UMC Utrecht portfolio CI